The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Buy the report here.

Smarter leaders trust GlobalData

Data Insights Immuno-Oncology - Thematic Research

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Regeneron Pharmaceuticals Inc

Grifols SA

Acorda Therapeutics Inc

Immatics NV

Lykera biomed SA

View all

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology

Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy). New generation of monoclonal antibodies (bi-specific antibodies) are considered active immunotherapies because they link immune cells and cancer cells to activate anti-cancer immune response. Due to their cancer-targeting properties, many different antibody therapies are currently being evaluated and several antibody-based immunotherapies have been approved.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 130+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cancer monoclonal antibody therapy.

Key players in cancer monoclonal antibody therapy – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to cancer monoclonal antibody therapy

Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy. The company is largely involved in immuno-oncology. Immatics undertakes the discovery of targets for cancer immunotherapies with the development of the right T-cell receptors. It has undertaken the development of adoptive cell therapies and TCR bispecifics.

In terms of application diversity, Immatics is the top company, followed by Regeneron Pharmaceuticals and Acorda Therapeutics. By means of geographic reach, Grifols holds the top position, while Acorda Therapeutics and Lykera Biomed are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.